| Literature DB >> 28413428 |
William Galbavy1, Yong Lu1, Martin Kaczocha1, Michelino Puopolo1, Lixin Liu1, Mario J Rebecchi1.
Abstract
BACKGROUND: We have previously reported elevated expression of multiple pro-inflammatory markers in the lumbar spinal cord (LSC) of middle-aged male rats compared to young adults suggesting a para-inflammatory state develops in the LSC by middle age, a time that in humans is associated with the greatest pain prevalence and persistence. The goal of the current study was to examine the transcriptome-wide gene expression differences between young and middle aged LSC.Entities:
Keywords: Aging; Complement; Inflammation; Microglia; Neuropathic; Spinal cord; T-cell; Transcriptome
Year: 2017 PMID: 28413428 PMCID: PMC5390443 DOI: 10.1186/s12979-017-0091-6
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Fig. 1Transcript expression ratio’s in middle-aged compared to young LSC. The mRNA transcript expression in the LSC of 3 month and 17-month-old Fisher 344 male rats were assessed and 21,700 probe sets were measureable. The horizontal axis indicates the log2 ratios of middle aged over young expression and the vertical axis is the –log10 of the FDR corrected p values. ~ 1100 transcripts were differentially expressed. Blue dots represent genes that increased or decreased by at least 1.5 fold (528)
Differential gene expression: largest effect sizes
| Gene | M/Y | Y Mean | M Mean | Annotation |
|---|---|---|---|---|
| Abp10 | 0.46 | 677 | 311 | Annexin V-binding protein |
| Aff4 | 0.45 | 458 | 204 | Transcription factor and central SEC component |
| Ago2 | 0.43 | 330 | 141 | RISC Catalytic Component 2 |
| Aqp4 | 0.50 | 2664 | 1329 | Aquaporin family member |
| Arl11 | 2.07 | 94 | 195 | ADP-ribosylation factor-like 11 |
| Asap1 | 0.40 | 524 | 212 | ADP-ribosylation factor (ARF) GTPase-activating protein |
| Bmpr2 | 0.46 | 970 | 449 | Bone morphogenetic protein receptor type II |
| C3 | 2.40 | 830 | 1996 | Central complement component |
| Chrdl1 | 2.48 | 60 | 148 | Ventroptin, antagonizes BMP actions |
| Clec12a | 2.18 | 99 | 215 | CTL/CTLD member, widely expressed in innate immune system |
| Cspp1 | 0.49 | 207 | 101 | Important for normal neural specific cilia function |
| Dnajb12 | 6.70 | 52 | 350 | DNAJ/HSP40 family member, regulates molecular chaperone activity, protein folding and degradation |
| Enc1 | 0.47 | 135 | 64 | Kelch-related family of actin-binding proteins, role in oxidative stress response, regulates Nrf2 |
| Falz | 0.50 | 482 | 239 | Transcription/epigenetic regulator, up-modulated in neurodegenerative diseases |
| Fcgr2b | 2.89 | 303 | 878 | Low affinity Fc receptor expressed in microglia |
| Fcrls | 2.78 | 218 | 607 | Fc receptor; part of TGFb1 microglial signature response |
| Fmo2 | 2.35 | 87 | 204 | Flavin-containing monooxygenase |
| Fstl3 | 2.13 | 66 | 142 | Secreted form binds/antagonizes members of TGF-b family, e.g., BMP2 |
| Gipr | 3.49 | 179 | 623 | Receptor for neuroprotective polypeptide GIP |
| Golga4 | 0.42 | 211 | 89 | Role in Rab6-regulated membrane-tethering events in the Golgi |
| Gpnmb | 3.14 | 420 | 1317 | Expressed in microglia, inflammatory response gene |
| Herc1 | 0.36 | 294 | 107 | Regulator of membrane trafficking |
| Kif1a | 0.38 | 3058 | 1160 | Kinesin family protein involved in syaptogenesis |
| Lgals3 | 2.44 | 927 | 2264 | Member galectin family of carbohydrate binding proteins; microglial marker and alt priming gene |
| Msi2 | 0.49 | 304 | 148 | RNA binding protein; role in CNS stem cell proliferation |
| Nrg1 | 0.46 | 553 | 253 | Neuregulin-1, signals through erb2/3 receptors, functions in neural development and plasticity |
| Pitpnm1 | 3.50 | 499 | 1749 | Transfers PtdIns from ER to plasma membrane |
| Postn | 2.73 | 147 | 402 | Aka periostin; enhances TGF-β signaling, facilitates BMP1, expressed in reactive microglia and astrocytes, neuroprotective |
| Pou3f1 | 2.16 | 266 | 574 | Transcription factor, promotes stem cell commitment to neural fate |
| RT1-EC2 | 2.50 | 75 | 189 | Class I MHC, up-modulated in spinal cord injury and neurodegeneration |
| S100a8 | 2.30 | 85 | 194 | Induced in macrophages and dendritic cells by TLR agonists, oxidative stress and corticosterone |
| Slc9a3 | 2.15 | 195 | 421 | Sodium/proton exchanger; Cation Proton Antiporter 3 |
| Tnc | 2.32 | 75 | 173 | Extracellular matrix protein, up regulated following CNS trauma |
| Unc5b | 0.47 | 995 | 469 | Netrin receptor family; required for axon guidance; maintains blood–brain barrier |
| Usp7 | 0.46 | 121 | 56 | Uiquitin-specific-processing protease 7, deubiquitinates range Deubiquitinates target proteins |
The annotated differential gene set (353) was filtered for largest effect sizes. Mean probe set expression levels (arbitrary units) for Y (young) and M (middle age) genes are shown
Confirmation of microarray results by qPCR
| Results | Lgals | Fcgr2b | Gpnmb | C3 | Atf3 | Ptprc | Cd163 | Nrg1 | Cd11b |
|---|---|---|---|---|---|---|---|---|---|
| ΔΔCt M v Y | 1.62 | 1.68 | 1.76 | 1.42 | 0.94 | 0.99 | 0.78 | −0.79 | 0.87 |
| qPCR Fold M/Y | 3.08 | 3.20 | 3.40 | 2.68 | 1.92 | 1.99 | 1.72 | 0.58 | 1.83 |
| Microarray M/Y | 2.44 | 2.89 | 3.14 | 2.40 | 1.73 | 1.84 | 1.59 | 0.46 | N/A |
| Adjusted | 0.004 | 0.003 | 0.006 | 0.010 | 0.004 | 0.001 | 0.001 | 0.056 | 1.0E-07 |
cDNA was synthesized from the same RNA samples analyzed in the microarrays. ΔΔCt values are expressed as described in Methods
Canonical pathways populated by the age-related gene set
| Pathway | Target Genes | Pathway Genes | Ratio | z-score | B-H | Target Gene ID’s |
|---|---|---|---|---|---|---|
| Complement | 9 | 37 | 0.243 | 1.414 | 1.11E-06 | C3, C1QA, C1QB, C1QC, C1S, CFD, CFH, ITGB2, SERPING1 |
| Cholesterol Biosynthesis | 7 | 28 | 0.250 | 2.63E-05 | CYP51A1, HMGCR, HMGCS1, HSD17B7, IDI1, LSS, SC5D | |
| iCOS-iCOSL signaling T helper cell | 10 | 108 | 0.093 | 6.64E-04 | CAMK2B, CD3G, FCER1G, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5, PDPK1, PLEKHA4, PTPRC | |
| Cholesterol Biosynthesis I | 4 | 13 | 0.308 | 1.84E-03 | CYP51A1, HSD17B7, LSS, SC5D | |
| Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) | 4 | 13 | 0.308 | 1.84E-03 | CYP51A1, HSD17B7, LSS, SC5D | |
| Cholesterol Biosynthesis II (via desmosterol) | 4 | 13 | 0.308 | 1.84E-03 | CYP51A1, HSD17B7, LSS, SC5D | |
| Ca-induced T cell Apoptosis | 7 | 64 | 0.109 | 2.40E-03 | CD3G, FCER1G, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5, PRKCE | |
| OX40-signaling | 8 | 89 | 0.090 | 2.40E-03 | CD3G, FCER1G, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5, RT1-EC2, TNFSF4 | |
| NFAT regulation of immune response | 11 | 171 | 0.064 | 1.89 | 2.40E-03 | BLNK, CD3G, FCER1G, FCGR2B, FCGR3A/FCGR3B, GNAS, GSK3B, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5 |
| B Cell development | 5 | 33 | 0.152 | 4.35E-03 | HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5, PTPRC | |
| Nur77 signaling in T cells | 6 | 57 | 0.105 | 6.70E-03 | CD3G, FCER1G, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5 | |
| Cd28 signaling in T Helper Cells | 8 | 118 | 0.068 | 1.15E-02 | CD3G, FCER1G, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5, PDPK1, PTPRC | |
| PKC-τ signaling in T cells | 8 | 118 | 0.068 | 1.414 | 1.15E-02 | CAMK2B, CD3G, FCER1G, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB5, MAP3K8 |
The differentially expressed annotated genes (target gene set) were placed in the contexts of canonical biological pathways using the IPA software and its curated database. Ratio = target genes/pathway genes. P values were calculated using a modified Fisher test that corrects for multiple hypothesis testing. Significant Z-score indicate overall pathway modulation (+) for up (-) for down
Populated upstream regulatory networks
| Upstream Regulator | Molecule Type |
| Target molecules in dataset | Mechanistic Network |
|---|---|---|---|---|
| IFNG | Pro-inflammatory cytokine produced mainly by activated T cells | 1.33E-16 | ABCA1,AIF1,ASS1,AVPR1A,BLNK,C1QA,C1QB,C1QC,C3,C4A/C4B,CCND2,CD163,CD74,CDH22,Cebpd,CP,CTGF,FAM107A,FCER1G,FCGR2B,FCGR3A,HLA-DQA1,HLADRA,HMGCR,HMGCS1,IDI1,IFITM1,IGF1,ITGB2,LGALS3,MAP3K8,MERTK,MT1E,PHACTR1,PLEK,PPARGC1B,RT1EC2,SERPING1,SLC6A6,SLC9A3,STAT6,TIMP1,TLR7,TREM2,TYROBP | CEBPA,FOXO3,Hdac,IFNG,IL1B,IL4,LDL,NFkBcomplex,PPARG,RUNX2,SP1,SP3,STAT1,STAT3,STAT5a/b,STAT6,TNF |
| Inosine | Metabolite with immunomodulatory effects | 4.15E-16 | AIF1,ANXA1,C1QA,C1QB,C1QC,C1S,C3,C4A/B,CFD,MS4a6b,MT1E,SERPING1,TIMP1 | |
| LPS | Major component of outer membrane of Gram-negative bacteria | 2.92E-14 | ABCA1,ANXA1,ANXA3,ASAP1,ASS1,AVPR1A,BMP2,C3,CCND2,CD163,CD37,CD53,CD74,CFD,CP,CSF3R,CTGF,DDX6,DIO2,EMR1,FCER1G,FCGR2B,Gp49a/Lilrb4,HLADQA1,IFITM1,IGF1,ITGB2,LGALS3,MAFF,MAP3K8,MERTK,MMP14,MT1E,MT1H,PDE4B,PLD4,PLEK,PPARGC1B,PYCARD,SLC9A3,SLFN13,STAT6,TIMP1,TLR7,TNFSF4,TREM2,TYROBP,VEZF1 | CEBPA,FOXO3,HDAC,IFNG,IL1B,IL4,IL6,NCOA1,NFkB (complex),PPARG,RUNX2,SP1,SP3,STAT1,STAT3,STAT4,STAT5a/b,STAT6,TNF,lipopolysaccharide |
| DYSF | Ca2+ sensor protein involved in synaptic vesicle fusion | 4.36E-12 | ABCA1,ANXA1,C1QB,CD53,CD74,CFD,FCGR2B,GP49a/Lilrb4,HLA-DQA1,LGALS3,LYZ1/LYZ2,TIMP1 | |
| Vancomycin | Antibiotic that exhibits significant neurotoxicity | 8.00E-12 | ANXA1,C3,C4A/C4B,CP,FMO2,GPNMB,LGALS3,MS4a6b,S100A11,SCD,TIMP1,TMEM173 | |
| TNF | Pro-inflammatory cytokine; In the CNS, derived mainly from activated microglia | 2.31E-11 | ABCA1,ANXA1,ASS1,AVPR1A,BIRC7,BMP2,C3,CCND2,CD163,Cebpd,CFD,CP,CTGF,FCER1G,FCGR2B,HERC1,HLADRA,HMGCR,HSD17B7,IFITM1,IGF1,ITGB2,LGALS3,LRG1,LSS,MAFF,MAP3K8,MMP14,MT1E,MT1H,PDE4B,PER2,POSTN,PPARGC1B,PYCARD,RGS4,SCD,SLC9A3,TIMP1,TLR7,TNR,TREM2 | CEBPA,CTNNB1,FOXO3,IFNG,IL1B,IL4,NFkB complex),PI3K complex,SP1,SP3,STAT1,STAT3,STAT5a/b,STAT6,TNF,estrogen receptor |
Members of the annotated differential gene set (353) were fit to regulatory networks in the IPA data base. P values are the probability that the observed overlap occurred by chance alone
Microglial and neuropathic pain-related gene expression
| Gene | M/Y | Microglial | Pain | Function |
|---|---|---|---|---|
| ABCA1 | 1.62 | Y | Y | Transporter of cholesterol and other lipids |
| AIF1 | 1.53 | Y | Y | Forms complexes with L-fimbrin in membrane ruffles and phagocytic cups; may modulate actin reorganization, facilitates cell migration and phagocytosis |
| ANXA3 | 1.55 | Y | Y | Annexin family member; up-regulated following tissue injury |
| ATF3 | 1.73 | Y | Y | Complexes with other transcriptional regulators; up-regulated in response to injury; negative regulator of TLR signaling; suppresses innate immune response |
| BLNK | 1.68 | Y | Cytoplasmic linker protein important in B cell development | |
| C1QA | 1.61 | Y | Y | Part of C1q complex; initial component of classic pathway |
| C1QB | 1.59 | Y | Y | Part of C1q complex |
| C1QC | 1.52 | Y | Y | Part of C1q complex |
| C4A | 1.98 | Y | Y | Cleaved by C1S; combines with C2 cleavage product forms C4b2b complex |
| CAMK2B | 0.64 | Y | Y | Ca2+/calmodulin-dependent protein kinase |
| CD163 | 1.59 | Y | M2 state microglial marker (aka, ED2); Alt priming gene | |
| CD37 | 1.54 | Y | Y | Interacts with dectin; regulates PAMP induced IL6 production; microglial sensome |
| CD53 | 1.71 | Y | Y | Contributes to transduction of CD2-generated signals in T cells |
| CD74 | 1.85 | Y | Y | Invariant MHCII component; processes receptor bound PAMP’S and DAMP’s for presentation to T cells |
| CSF3R | 1.59 | Y | Y | Binds GCSF, which increases M2 state marker expression, and inhibits pro-inflammatory cytokine expression, while promoting neurotrophic factor expression. |
| CXCL9 | 1.68 | Y | Y | Ligand for Cxcr3 receptor, activated by TLR ligands and pro-inflammatory cytokines; appears to regulate T cell migration |
| Egr2 | 1.96 | Y | Transcription factor; Alt priming gene | |
| EMR1 | 1.81 | Y | Y | Member of adhesion GPCR receptors; required to activate CD8+ regulatory T cells |
| FAM105A | 2.08 | Y | Y | |
| FCER1G | 1.74 | Y | Y | High affinity Fc epsilon receptor; binds TREM2; involved in response to apoptotic debris, immune complexes through C1q complex |
| FCGR2B | 2.89 | Y | Y | Fc receptor, IgG, low affinity; binds Cxcl7 (CD32B); inhibitory |
| FCGR3A | 1.52 | Y | Y | Aka CD16a; similar to FCGR2B |
| FCRLS | 2.78 | Y | Fc immunoglobulin receptor; part of TGFb1 microglial signature response | |
| GOLM1 | 1.53 | Y | Assists transport of cargo through Golgi apparatus; AD risk gene | |
| IGF1 | 0.65 | Y | Neurotrophic factor; increased by IL4/MCSF; M2 phenotype and Alt priming gene | |
| IGFBP6 | 1.53 | Y | Y | Binds IGF’s and modulates their growth factor effects |
| ITGB2 | 1.73 | Y | Y | CD18; integrin beta chain beta 2; involved in leukocyte adhesion |
| LGALS3 | 2.44 | Y | Galectin family; inflammatory factor (MAC2); microglial marker; Alt priming gene | |
| PTPRC | 1.84 | Y | Y | Protein tyrosine phosphatase; aka CD45; enriched in microglia; opposes microglial activation |
| PYCARD | 1.50 | Y | Y | Mediator of apoptosis and inflammation; adapter for inflammasome assembly |
| TLR7 | 1.84 | Y | Y | TLR (nucleotide sensing); signals via MyD88 pathway; can modulate other TLR’s |
| TMEM173 | 1.52 | Y | Y | Facilitates innate immune signaling; promotes expression of IFN-alpha and IFN-beta; |
| TREM2 | 1.74 | Y | Forms signaling complex with TYROBP; M2 state and sensome gene; promotes microglial expansion; up-regulated by IL4; critical for normal phagocytosis | |
| TYROBP | 1.82 | Y | Y | Forms signaling complex with TREM2; activates microglia; required for synaptic pruning |
The annotated differentially expressed gene set (353) was compared to previously published consensus genes specific for microglia. Those relevant to establishment of neuropathic pain are indicated